Evidence map›Paper›PMID 33477954›Full record

ArticleJournal of clinical medicine2021

Low Luminance Visual Acuity and Low Luminance Deficit in Proliferative Diabetic Retinopathy.

Eleni Karatsai, Piyali Sen, Sarega Gurudas, Sobha Sivaprasad

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Posterior Retinal Ischemia Correlates With Vision in Patients With Diabetes.Investigative ophthalmology & visual science · 2025
    Observational
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Eleni KaratsaiNIHR Moorfields Biomedical Research Centre, London EC1V 2PD, UK.
Piyali SenNIHR Moorfields Biomedical Research Centre, London EC1V 2PD, UK.ORCID 0000-0002-1885-4624
Sarega GurudasInstitute of Ophthalmology, University College, London EC1V 9EL, UK.
Sobha SivaprasadNIHR Moorfields Biomedical Research Centre, London EC1V 2PD, UK.ORCID 0000-0001-8952-0659
NIHR Moorfields Biomedical Research Centre · GBUniversity College London · GB

Funding

Department of Health 12/66/15
6 · The paper itself

Abstract

This study aimed to determine the relation of best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA) in proliferative diabetic retinopathy (PDR) following treatment with either aflibercept or pan-retinal photocoagulation (PRP). The study was conducted as a post-hoc analysis of the CLARITY trial in which naïve and PRP treated PDR patients were randomised to receive either aflibercept or PRP. BCVA and LLVA were assessed at baseline and at week 52. Our analyses showed that the BCVA and LLVA correlate well in treatment naïve PDR with an average low luminance deficit of 11.79 Early Treatment Diabetic Retinopathy Score (ETDRS) letters. However, LLVA at lower levels of BCVA showed more variance. Post aflibercept therapy, the mean change in BCVA and LLVA at 52 weeks after aflibercept was +2.1 (SD 6.05) letters and +0.39 (SD 5.6) letters, respectively. Similarly, after PRP, it was -2.5 (SD 4.9) letters and -1.9 (SD 8.7) letters, respectively. When comparing treatment arms, BCVA change was found to be statistically significant (

Indexed as

afliberceptbest corrected visual acuitylow luminance deficitlow luminance visual acuitypan-retinal photocoagulationproliferative diabetic retinopathy

Identifiers

PMID33477954
PMCPMC7835861
OpenAlexW3122187971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.